Clinical Trials Logo

Filter by:
NCT ID: NCT01417832 Completed - Dental Caries Clinical Trials

Radiographic Progression of Sealed and Infiltrated Caries Lesions in Vivo

Start date: January 2008
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study was to compare with a clinical randomized controlled split-mouth design study the changes in the therapeutic effect of infiltrating versus sealing proximal caries lesions and placebo treatment after 1, 2 and 3 years. The outcome was lesion progression, evaluated by radiographic techniques.

NCT ID: NCT01415427 Completed - MPS IVA Clinical Trials

Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Start date: July 2011
Phase: Phase 3
Study type: Interventional

This Phase 3 extension study will evaluate the long-term efficacy and safety of BMN 110 2.0 mg/kg/week and/or BMN 110 2.0 mg/kg/every other week in patients with mucopolysaccharidosis IVA (Morquio A Syndrome).

NCT ID: NCT01412723 Completed - Iron Deficiency Clinical Trials

Ferrous Sulfate Versus Iron Amino Acid Chelate

Start date: October 2011
Phase: Phase 3
Study type: Interventional

Iron deficiency and depleted levels of iron are the most prevalent nutritional deficiency and the leading cause of anemia in the world; this can occur at any age, but preschool children are at particular risk of developing it. This condition may cause serious repercussions for life, being a public health threat of considerable importance worldwide. Food fortification is considered the most effective solution to counter this situation, because it can help more people than other solutions. It is going to carry out a community trial to compare the efficacy of ferrous sulfate with respect to iron amino acid chelate as a dietary supplement in preschool children of Medellin with depleted levels of iron; in terms of increasing ferritin levels in blood and maintain hemoglobin levels. It is hypothesized that at the end of the study the effect of milk fortified with iron amino acid chelate won't be less than the effect of fortified with ferrous sulfate. It is hoped that the results may contribute, albeit indirectly, to improve the health status of children with depleted levels of iron whom consume iron-fortified products.

NCT ID: NCT01405196 Completed - Clinical trials for Lupus Erythematosus, Systemic

Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus

BUTTERFLY
Start date: December 2011
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate and compare efficacy of 3 dose levels of PF-04236921 to placebo in subjects with generalized lupus using a measure called the Systemic Lupus Erythematosus (SLE) Responder Index. The study will evaluate secondary and exploratory measures as well.

NCT ID: NCT01403090 Completed - Pulmonary Embolism Clinical Trials

Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism

Start date: December 2011
Phase: Phase 1
Study type: Interventional

The Angel™ Catheter combines the functions of a vena cava filter and a multi-lumen central line catheter. The device is designed to be placed in the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous system. The primary endpoint is freedom from serious adverse events (SAE), defined as death, symptomatic pulmonary embolism or major bleeding .

NCT ID: NCT01397786 Completed - Schizophrenia Clinical Trials

Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia

ZENITH
Start date: September 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as monotherapy in adults with schizophrenia.

NCT ID: NCT01396447 Completed - Depression, Bipolar Clinical Trials

Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression

Start date: July 26, 2011
Phase: Phase 2
Study type: Interventional

The objective of this study was to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of participants with bipolar depression.

NCT ID: NCT01395745 Completed - Clinical trials for Systemic Lupus Erythematosus

CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus

CHABLIS-SC1
Start date: February 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of subcutaneous blisibimod administered in addition to standard therapy in subjects with active Systemic Lupus Erythematosus (SLE) disease as defined by SELENA-SLEDAI score ≥10 despite on-going stable corticosteroid therapy.

NCT ID: NCT01394952 Completed - Clinical trials for Diabetes Mellitus, Type 2

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

REWIND
Start date: July 22, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to assess whether dulaglutide can reduce major cardiovascular events and other serious outcomes in persons with type 2 diabetes, when added to their anti-hyperglycemic regimen.

NCT ID: NCT01393639 Completed - Clinical trials for Rheumatoid Arthritis

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Start date: September 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the safety and efficacy of multiple doses of PF-04171327, an experimental glucocorticoid drug, to prednisone at 5 mg or 10 mg and placebo in the treatment of rheumatoid arthritis. All subjects will also be receiving background treatment of methotrexate for their rheumatoid arthritis. Study medication will be given for eight weeks followed by a 4 week period during which the dose of study medication will be gradually reduced. The efficacy of the study medications will be determined by assessing severity of the rheumatoid arthritis during the study and safety will be determined by adverse event reporting, laboratory tests and biomarker analysis.